TrialAlimentary pharmacology & therapeutics2017

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.

W D Chey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.